Malmström, Rickard E., Godman, Brian B., Diogene, Eduard, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen, Ferrario, Alessandra, Finlayson, Alexander E., Fürst, Jurij, Garuoliene, Kristina, Gomes, Miguel, Gutiérrez-Ibarluzea, Iñaki, Haycox, Alan, Hviding, Krystyna, Herholz, Harald, Hoffmann, Mikael, Jan, Saira, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Langner, Irene, Lonsdale, Julie, Lööv, Sven-Äke, Malinowska, Kamila, McCullagh, Laura, Paterson, Ken, Markovic-Pekovic, Vanda, Martin, Andrew, Piessnegger, Jutta, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Tulunay, Cankat, Tomek, Dominik, Vončina, Luka, Vlahovic-Palcevski, Vera, Wale, Janet, Wilcock, Michael, Wladysiuk, Magdalena, Woerkom, Menno van, Zara, Corrine and Gustafsson, Lars L. (2013) Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology, 4 (39). ISSN 1663-9812
Full text not available from this repository.Abstract
There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have shown dabigatran to be cost-effective but there are budget concerns given the prevalence of AF. There are also issues with potentially re-designing anticoagulant services. This has resulted in activities across countries to better manage its use.
| Item Type: | Article |
|---|---|
| Official URL: | http://www.frontiersin.org/Pharmaceutical_Medicine... |
| Additional Information: | © 2013 The Authors |
| Divisions: | Social Policy LSE Health |
| Subjects: | R Medicine > RM Therapeutics. Pharmacology |
| Date Deposited: | 30 Aug 2013 13:48 |
| Last Modified: | 14 Sep 2024 05:58 |
| Funders: | Karolinska Institutet, Sweden |
| URI: | http://eprints.lse.ac.uk/id/eprint/52178 |
Actions (login required)
 |
View Item |
